Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Precision launches $80.5m public offering:

This article was originally published in Clinica

Executive Summary

Precision Therapeutics, the developer of the ChemoFx test for assessing the efficiency of various cancer therapies, is aiming to raise $80.5m through a public flotation on the Nasdaq stock exchange. The Pittsburgh, Pennsylvania-based firm did not disclose the amount of shares offered or the price range expected for the IPO, but it did indicate that the proceeds would be split between expansion of ChemoFx's sales and marketing capabilities, the funding of R&D programmes and clinical studies, and general corporate expenses, including the potential expansion of laboratory facilities. Precision posted revenues of $846,000 and a net loss of $8.6m in fiscal 2006. Most recently, it recorded half year revenues of $926,000 for 2007.






Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts